EyeBio

EyeBio is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases.

https://eyebiotech.com/

11-50 employees

Growth Trajectory

EyeBio intends to expand globally to help patients worldwide by advancing its pipeline of retinal disease candidates. The company is focused on developing innovative ophthalmology therapies and exploring targets like the Wnt signaling pathway. Supported by Merck's resources, EyeBio aims to be at the forefront of ophthalmology therapy through innovation and a commitment to improving patient outcomes.

Technical Challenges

Reducing vascular leakage in retinal vascular diseases.

Restoring the integrity of the blood-retinal barrier.

Developing therapies for complex retinal diseases like DME and NVAMD.

Tech Stack

Team Size

Key Risks

Competition in the biopharmaceutical industry and the development of new products and patents by competitors.

Pharmaceutical industry regulation and healthcare legislation could impact development and approval timelines.

Challenges in addressing the unmet medical needs of patients with complex retinal diseases like DME and NVAMD.

Opportunities

Leveraging the Wnt signaling pathway as a novel target for reducing vascular leakage and restoring the blood-retinal barrier.

Expanding global market reach to address the needs of patients with retinal diseases worldwide.

Furthering the collaboration between Merck and EyeBio to accelerate the development of retinal disease candidates.

Live Data Stream

Access Our Live VC Funding Database

30,000+ funded startups

tracked in the last 3 months

B2B verified emails

of key decision makers

Growth metrics

Real-time company performance data

Live updates

of new VC funding rounds

Advanced filters

for sophisticated queries

API access

with multiple export formats

Access Database

Updated every 5 minutes